Guideline Recommendations for Management of Wolff‑Parkinson‑White (WPW) Syndrome

1. Definitive Treatment

• Catheter ablation is the definitive, first‑line therapy for symptomatic WPW patients, especially those with documented arrhythmias, syncope, or high‑risk features. This is a Class I recommendation from the American College of Cardiology (ACC). 1
• Ablation achieves cure rates > 95 % in experienced centers. (Class I, ACC) 7

2. Risk Stratification (High‑Risk Features)

• Patients with any of the following are at highest risk of sudden cardiac death and should be considered for immediate ablation:

3. Acute Management of WPW‑Related Arrhythmias

3.1 Hemodynamically Unstable Patients

• Immediate synchronized electrical cardioversion is mandatory for unstable WPW patients with atrial fibrillation and rapid ventricular response, to prevent ventricular fibrillation. (Class I, ESC) 4

3.2 Hemodynamically Stable Patients with Pre‑excited AF (wide QRS ≥ 120 ms)

• First‑line intravenous procainamide (Class I, ACC) 4
• First‑line intravenous ibutilide (Class I, ACC) 4
• Alternative options (Class IIa/IIb):

3.3 Orthodromic AVRT (narrow QRS < 120 ms)

• Vagal maneuvers (Class I, ESC) 3
• Intravenous adenosine (Class I, safe because conduction is AV‑node dependent) (ESC) 4
• Synchronized cardioversion if vagal maneuvers and adenosine fail (Class I, ESC) 3

4. Medications Contra‑Indicated in Pre‑excited AF (Class III – Harm)

• Digoxin (oral or IV) – promotes AV‑node block, favoring accessory‑pathway conduction. (ESC) 4
• Diltiazem – same mechanism. (ESC) 4
• Verapamil – same mechanism. (ESC) 4
• Intravenous amiodarone – may facilitate ventricular fibrillation. (ACC) 1
• Adenosine when QRS is wide/pre‑excited – can precipitate VF. (ACC) 1
• Beta‑blockers – ineffective for rate control and may cause adverse hemodynamics. (ESC) 4

These agents increase AV‑node refractoriness, encouraging preferential conduction down the accessory pathway and raising the risk of ventricular fibrillation. (ESC) 4

5. Management of Asymptomatic WPW Pattern

• The 10‑year risk of sudden death in asymptomatic individuals is 0.15–0.24 %, with the highest risk occurring in the first two decades of life. (ESC) 3

6. Long‑Term Medical Management When Ablation Is Not Performed

• Class IA anti‑arrhythmic agents (quinidine, procainamide, disopyramide) prolong the accessory‑pathway refractory period and may be used for rhythm control. (ESC) 4
• For rate control of orthodromic AVRT with narrow QRS, oral beta‑blockers, diltiazem, or verapamil are acceptable, but must never be used in pre‑excited atrial fibrillation. (ESC) 3

7. Common Pitfalls to Avoid

• Never administer AV‑nodal blocking agents (e.g., digoxin, beta‑blockers, calcium‑channel blockers, adenosine) in wide‑complex tachycardia or pre‑excited atrial fibrillation, as this can precipitate ventricular fibrillation. (ACC/ESC) 4
• Do not delay cardioversion in hemodynamically unstable patients; immediate electrical conversion is essential. (ESC) 4
• Successful ablation does not guarantee prevention of future atrial fibrillation, especially in older patients; ongoing monitoring and possible adjunctive therapy may be required. (ESC) 4